[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neonatal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neonatal":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,75,100,135,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100652538","the-effect-of-infant-massage-applied-at-different-durations-on-comfort-and-physiological-stability-in-late-preterm-infants-receiving-ncpap-100652538",false,"NCT07773896","The Effect of Infant Massage Applied at Different Durations on Comfort and Physiological Stability in Late Preterm Infants Receiving nCPAP","Inclusion Criteria:\n\n* Newborns must:\n* Be between 34⁰\u002F₇ and 36⁶\u002F₇ weeks of gestation,\n* Be receiving nCPAP support,\n* Be hemodynamically stable,\n* Have started enteral feeding,\n* Have no congenital anomalies,\n* Their parents must voluntarily agree to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Newborns who:\n* Are receiving invasive mechanical ventilation,\n* Have undergone a surgical procedure,\n* Have a neurological disorder or a serious congenital anomaly,\n* Are receiving sedatives or neuromuscular blocking agents,\n* Whose clinical condition is not suitable for massage,\n* Who have a dermatological condition that could compromise skin integrity or a skin lesion that could interfere with massage,\n* Who have medical device-related pressure injuries caused by nCPAP.",true,"ALL","1 Day","1 Month",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","Aim: The aim of this study is to investigate the effects of massage administered for varying durations on comfort levels and physiological stability in late-preterm newborns receiving nCPAP. Method: The study will be conducted between Agust 2026 and June 2027 at the Neonatal Intensive Care Unit of Tarsus State Hospital with late preterm infants who will receive nCPAP therapy. Late preterm infants scheduled to receive nCPAP therapy (a total of 90 infants) will be divided into three groups (intervention group 1: 30; intervention group 2: 30; control group: 30). The pre-procedure comfort levels of all newborns will be assessed using the COMFORTneo Scale. In addition, the infants' heart rate, respiratory rate, oxygen saturation, and body temperature will be recorded. In addition to standard clinical procedures, newborns in the first intervention group will receive massage for 5 minutes twice daily for 3 days, in addition to routine clinical care. Newborns in the second intervention group will receive massage for 10 minutes twice daily for 3 days, in addition to routine clinical care. Newborns in the control group will not receive any additional intervention; only the clinic's routine care protocols will be followed.\n\nAfter each massage session is completed, the newborns' comfort levels will be reassessed using the COMFORTneo Scale; heart rate, respiratory rate, oxygen saturation, and body temperature will be recorded. This procedure will be repeated for each session throughout the 3-day intervention period, and all measurements will be recorded on the follow-up form.",[27,28],"Neonatal","Preterm",[30,31],"nCPAP","massage","NOT_YET_RECRUITING","2026-08-15",{"date":35,"type":36},"2026-08-19","ACTUAL",{"date":38,"type":21},"2026-09-25",{"date":40,"type":21},"2027-06-01",{"name":42,"class":43},"Tarsus University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":15,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":44},"100639038","generating-intervals-of-reference-ffor-early-life-brain-biomarkers-100639038","NCT07585149","Generating Intervals of Reference FFor Early Life Brain Biomarkers.","GIRAFFE","Inclusion Criteria:\n\n* Term neonate (≥37 weeks)\n* Planned routine venous blood drawn within one week of life\n* Relevant demographic\u002Fclinical information available, including gestational age, day of life, birth weight, sex, race, mode of delivery, and 5-minute Apgar score\n* Informed parental consent obtained prior to any study procedures\n\nExclusion Criteria:\n\n* Pre-term neonates \\\u003C37 weeks\n* Any clinical evidence of neurological\u002F CNS abnormalities.\n* NICU admission\n* Any neonates with Suspected or culture-positive sepsis or meningitis Any known inborn errors of metabolism (IEM). Any known chromosomal abnormalities or any apparent congenital abnormalities\n* When the relevant demographic\u002Fclinical information is not available.","0 Days","7 Days",{"count":55,"type":21},150,"OBSERVATIONAL","Highly sensitive immunoassays for the detection of neuro-specific biomarkers are becoming more accessible. Currently, the majority of these biomarkers are detected with the use of labour-intensive and highly skilled wet lab work. However, recent advancements have allowed for the introduction of these neuro-specific biomarkers into mainstream clinical chemistry analysers, bringing them closer to clinical care. There is a vast amount of published literature for neuro-specific biomarkers in an adult and ageing population, unfortunately, the same cannot be said for the neonatal population. From the limited available literature, clear differences are being documented in physiological levels of neuro-specific biomarkers in adults and infants. Neuro-specific biomarkers such as GFAP (Glial Fibrillary Acidic Protein) and Tau are demonstrating promise for the early detection and prediction of neuro-developmental disorders. There is a need for an understanding of physiological levels of these neuro-specific biomarkers in a neonatal population before they can be fully adopted into clinical routine. The development of a neonatal reference interval for neuro-specific biomarkers may provide a foundation for the accurate interpretation of neuro-specific biomarker elevations in neonatal brain injury, aiding in the development of biomarker-based screening tools for early diagnosis and intervention.",[59,60,27],"Reference Intervals","Biomarker in Early Diagnosis",[62,63,27,64],"Neurospecific","Biomarker","Reference Interval","RECRUITING","2026-05-08",{"date":68,"type":36},"2026-05-13",{"date":70,"type":36},"2026-04-13",{"date":72,"type":21},"2027-06-30",{"name":74,"class":43},"University College Cork",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100607592","against-chikungunya-virus-and-neonatal-infection-100607592","NCT07190560","Against Chikungunya Virus and Neonatal Infection","ConvictionCHIK","Inclusion Criteria:\n\n* Treatment group\n\nNewborn:\n\n* whose mother has a clinical and\u002For laboratory diagnosis of Chikungunya (CHIK) infection occurring between 2 days before and 2 days after birth.\n* Hospitalized in a Level III neonatology unit in Mayotte or at the University Hospital of La Réunion.\n* Eligible for experimental treatment (called PC-CHIK-V):\n\n  * If the maternal infection was diagnosed between2 days before and the day of delivery, treatment can be administered within the first 12 hours of the newborn's life.\n  * If the maternal infection was diagnosed between 1 day and 2 days after birth, treatment can be administered within 12 hours of diagnosis.\n* Whose holders of parental authority have given free, informed, and written consent prior to any examination required for the research. Parallel Cohort of\n\nUntreated Newborns (parallel observational cohort)\n\nNewborns:\n\n* Whose mother has a clinical and\u002For laboratory diagnosis of CHIK-V infection occurring between 2 days before and 2 days after birth.\n* Hospitalized in a Level III neonatology unit in Mayotte or at the University Hospital of La Réunion.\n* Not treated with PC-CHIK-V:\n* Monitored in one of the units of the Neonatology Department for at least 5 days from the day of birth.\n* Whose holders of parental authority (or the holder if the mother is the sole holder of parental authority) have been informed of the research and have not objected to the use of data collected during hospitalization for research purposes.\n\nExclusion Criteria:\n\n* Newborns who present at birth with clinical criteria for ahypoxic-ischemic encephalopathy (HIE) that require therapeutic hypothermia according to the national protocol for \"neonatal therapeutic hypothermia\"\n* Newborns who require phototherapy treatment at the time of enrollment using devices with a maximum energy wavelength less than 425 nm and\u002For with an emission bandwidth with a lower limit of \\\u003C375 nm.","2 Days",{"count":84,"type":21},60,[24],"The goal of this clinical trial is to learn if administration of plasma, from a whole blood donation from an individual who has declared a Chikungunya infection for less than 6 months , to a newborn, whose mother has a peripartum chikungunya infection, will have an impact on the proportion of newborns surviving without encephalitis\u002Fencephalopathy (EE) within the first 5 days of life. Researchers will compare results to an observational study of 30 newborns who couldn't have been proposed to participate at the clinical trial, because of delay of diagnosis or delay of transfer to hospital which doesn't allow transfusion or parents not accepting plasma transfusion to the newborn.\n\nParticipants of the clinical trial will:\n\n* receive a transfusion,\n* visit the clinic and undergo biological tests every day until day 7 and once between 1 and 3 months.\n\nParticipant of observational study as part of their regular medical care, and biological data will be reused for the research from the mother's diagnosis until the newborn reaches 3 months of age",[88,27,89,90],"Chikungunya Virus Infection","Transfusion","Encephalopathy","2026-05-04",{"date":66,"type":36},{"date":94,"type":21},"2026-08-01",{"date":96,"type":21},"2027-12-01",{"name":98,"class":43},"Centre Hospitalier Universitaire de la Réunion",2,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":15,"sex":16,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":120,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":134},"100568106","neonatal-platelet-transfusion-threshold-trial-100568106","NCT06676904","Neonatal Platelet Transfusion Threshold Trial","NeoPlaTT","Inclusion Criteria:\n\n* Gestational age of 23 0\u002F7 to 26 6\u002F7 weeks\n* Postnatal age of \\\u003C 48 hours\n\nExclusion Criteria:\n\n* Comfort care or withdrawal of care planned\n* Neonatal alloimmune thrombocytopenia or suspected\u002Fconfirmed congenital platelet or bleeding disorder\n* Receipt of platelet transfusion\n* No receipt of Vitamin K\n* Parents\u002Fguardian decline consent","1 Hour","48 Hours",{"count":110,"type":21},2433,[24],"The objective of the NeoPlaTT trial is to test whether, among extremely preterm infants born at 23 0\u002F7 to 26 6\u002F7 weeks' gestation, a lower platelet transfusion threshold, compared to a higher threshold, improves survival without major or severe bleeding up to 40 0\u002F7 weeks' postmenstrual age (PMA).",[114,27,115,116,117,118,119],"Thrombocytopenia","Platelet Transfusion","Infant, Newborn, Diseases","Infant, Extremely Low Birth Weight","Infant, Small for Gestational Age","Thrombosis",[121,122,123],"platelet transfusion","neonatal","thrombosis","2026-03-24",{"date":126,"type":36},"2026-03-25",{"date":128,"type":36},"2025-06-13",{"date":130,"type":21},"2031-04-30",{"name":132,"class":133},"NICHD Neonatal Research Network","NETWORK",20,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":15,"sex":142,"minAge":143,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":159,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":44},"100619990","mindfulness-and-meditation-based-lactation-education-on-maternal-breastmilk-in-the-neonatal-icu-100619990","NCT07351799","Mindfulness and Meditation Based Lactation Education on Maternal Breastmilk in the Neonatal ICU","The Impact of Mindfulness and Meditation Based Lactation Education on Maternal Breastmilk in the Neonatal ICU: Intervention Study","Inclusion Criteria:\n\n* Maternal age \\> 20 years of age\n* Read, write and understand English\n* Infant NICU admit\n* Infant birthplace of Rochester, MN (Mayo Clinic)\n* Maternal adherence to pumping ≥ 8 times in 24 hours\n* Mother enrolled within 72 hours of birth\n* Gestational age of neonate at birth of \\\u003C 34 0\u002F7 weeks\n\nExclusion Criteria:\n\n* Maternal extensive existing mindfulness practice\n* Maternal breast\u002Fchest surgery\n* Maternal polycystic ovarian syndrome (PCOS)\n* Maternal current illicit substance abuse\n* Diagnosis of maternal current severe mental health concerns\n* Maternal multiple gestation (twins or higher order) pregnancy and delivery","FEMALE","20 Years",{"count":145,"type":21},40,[24],"The purpose of this research is to investigate associations between mindfulness and meditation techniques and changes in maternal breastmilk in the mother pumping for her NICU infant.",[149,150,151,152,27,153,154,155,156,157,158],"Lactation","Mindfulness","NICU","Breastmilk","Meditation","Pumping, Breast","Cortisol","Oxytocin","Anxiety","Depression",[160,161,151,162,27,163,164,165,166,167,158],"lactation","mindfulness","breastmilk","meditation","pumping, breast","cortisol","oxytocin","anxiety","2026-01-12",{"date":170,"type":36},"2026-01-20",{"date":172,"type":36},"2025-09-22",{"date":174,"type":21},"2026-11-02",{"name":176,"class":43},"Mayo Clinic",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":44},"100600849","phase-2-comparison-of-zinc-and-probiotics-on-neonates-with-indirect-hyperbilirubinemia-undergoing-phototherapy-100600849","NCT07102836","COMPARISON OF ZINC AND PROBIOTICS ON NEONATES WITH INDIRECT HYPERBILIRUBINEMIA UNDERGOING PHOTOTHERAPY","COMPARATIVE EFFECTS OF ZINC AND PROBIOTICS ON NEONATAL INDIRECT HYPERBILIRUBINEMIA UNDERGOING PHOTOTHERAPY","ZIPP","Inclusion Criteria:\n\n* 1\\. Term or Near term neonates 2. Age \\\u003C7 days at enrollment 3. Bilirubin levels within phototherapy range according to NICE bilirubin threshold charts 4. No identifiable pathology 5. Tolerating oral feeds 6. Parental or Guardian written informed consent taken.\n\nExclusion Criteria:\n\n* 1\\. Positive sepsis screen or clinical signs of infection 2. Direct hyperbilirubinemia 3. Gastrointestinal malformations 4. Oral intolerance 5. Requiring mechanical ventilation 6. Congenital anomalies 7. Parental or Guardian refusal to participate in study","28 Days",{"count":187,"type":21},110,[189],"PHASE2","Study will evaluate effects of oral zinc and probiotics supplementation in neonates who have indirect hyperbilirubinemia and are receiving phototherapy. Aim is to compare efficacy of these two drugs in clearing bilirubin and reducing duration of phototherapy. Neonates will be randomly assigned to receive either drug alongside phototherapy.",[192,27],"Indirect Hyperbilirubinemia",[194,195,196,197,198,199,200,201,192],"Zinc","Probiotics","Jaundice","Phototherapy","Neonates","Randomized Controlled Trial","Bilirubin","Enterohepatic Circulation","2025-07-30",{"date":204,"type":36},"2025-08-05",{"date":206,"type":21},"2025-08-07",{"date":208,"type":21},"2026-05-07",{"name":210,"class":43},"Quaid-e-Azam Medical College"]